Author + information
This research is to explore the clinical effects of treatment with Tirofiban for high-risk non-ST-segment elevation acute coronary syndrome (NSTE ACS) during peri-operative intervention operation period, and to improve the level of clinical treatment.
90 cases of high-risk NSTE ACS patients were randomly selected from January, 2013 to April, 2016 as the research objects, which were divided into the control group and the observation group. The control group received clopidogrel anticoagulation, coronary angiography and percutaneous coronary interventional (PCI) treatment, while the observation group took tirofiban treatment in addition to the treatment of control group. The differences on major adverse cardiovascular events, TIMI flow grading and complications of the two groups were observed after treatment.
There was significant difference (P < 0.05) on the distal vascular blockage of major adverse cardiovascular events, intra-operative no-reflow, reoccurrence of acute myocardial infarction and stenocardia and post-PCI TIMI flow grade 2 and 3. But in terms of bleeding complications, TIMI flow grade 0 and 1 before PCI and after PCI, there was no significant difference (p> 0.05).
Application of tirofiban treatment for high-risk NSTE ACS during the peri-intervention period is safe and effective, which can improve TIMI flow, increase tissue perfusion and reduce postoperative complications.